

AMENDMENTS TO THE CLAIMS

This listing of claims will replace all prior versions and listings of claims in the application:

1-7. (withdrawn)

8. (currently amended) A polypeptide produced by a process comprising growing a culture of a host cell in suitable culture medium and isolating the polypeptide from culture, wherein the host cell comprises a nucleic acid molecule comprising a nucleic acid sequence selected from:

~~a) a nucleotide sequence as set forth in Figure 1A (SEQ ID NO: 1);~~

~~b) a nucleotide sequence encoding a polypeptide from residues 1-200 or from residues 21-200 as set forth in Figure 1A (SEQ ID NO: 2);~~

~~c) a nucleotide sequence encoding a polypeptide that is at least about 70 percent identical to a polypeptide as set forth in Figure 1A (SEQ ID NO: 2), wherein the complement of the polypeptide has at least one activity characteristic of CRP1;~~

~~d) a nucleotide sequence complementary to any of (a), (b), or (c);~~

~~e) a nucleotide sequence of (b) or (c) encoding a polypeptide fragment of at least about 50 amino acid residues, wherein the polypeptide fragment has at least one activity characteristic of CRP1;~~

~~f) a nucleotide sequence comprising a fragment of at least about 75 nucleotides of the sequence as set forth in Figure 1A (SEQ ID NO: 1), wherein the polypeptide has at least one activity characteristic of CRP1;~~

~~g) a nucleotide sequence that hybridizes over its entire length under high stringency conditions to any of (a)-(f);~~

FINNEGAN
HENDERSON
FARABOW
GARRETT &
DUNNER LLP

1300 I Street, NW
Washington, DC 20005
202.408.4000
Fax 202.408.4400
www.finnegan.com

a) ~~[[h]]~~ a nucleotide sequence as set forth in Figure 2A (SEQ ID NO: 6) or Figure 3A (SEQ ID NO: 11);

b) ~~[[i]]~~ a nucleotide sequence encoding the polypeptide as set forth in Figure 2A (SEQ ID NO: 7) from residues 1-322 or from residues 47-322, or as set forth in Figure 3A (SEQ ID NO: 12) from residues 1-288 or from residue 19-288, 20-288, 21-288, 22-288, 24-288, or 28-288;

c) ~~[[j]]~~ a nucleotide sequence encoding a polypeptide that is at least about 95 ~~[[70]]~~ percent identical to the polypeptide as set forth in Figure 2A (SEQ ID NO: 7) or Figure 3A (SEQ ID NO: 12), wherein the polypeptide has at least one activity characteristic of B7RP1 selected from a T-cell proliferation activity, a T-cell activation activity, and a binding activity to CRP1;

~~k) a nucleotide sequence complementary to any of (h), (i), or (j);~~

d) ~~[[l]]~~ a nucleotide sequence of (b) or (c) ~~(i) or (j)~~ encoding a polypeptide fragment of at least about 50 amino acid residues, wherein the polypeptide fragment has at least one activity characteristic of B7RP1 selected from a T-cell proliferation activity, a T-cell activation activity, and a binding activity to CRP1;

e) ~~[[m]]~~ a nucleotide sequence comprising a fragment of at least about 75 nucleotides of the sequence as set forth in Figure 2A (SEQ ID NO: 6) or Figure 3A (SEQ ID NO: 11), wherein the polypeptide has at least one activity characteristic of B7RP1 selected from a T-cell proliferation activity, a T-cell activation activity, and a binding activity to CRP1; and

f) ~~[[n]]~~ a nucleotide sequence that hybridizes over its entire length to any of (a)-
(e) under high stringency conditions comprising a hybridization medium of 50%
(volume/volume) formamide with 0.1% bovine serum albumin/0.1% Ficoll/0.1%

polyvinylpyrrolidone/50 mM sodium phosphate buffer at pH 6.5 with 5 x SSC at 42°C and washes at 42°C in 0.2 x SSC and 0.1% SDS, where the polypeptide encoded by the complement of the sequence has at least one activity selected from a T-cell proliferation activity, a T-cell activation activity, and a binding activity to B7RP1 to any of (h)-(m); and

g) [(k)] a nucleotide sequence complementary to any of (a)-(f) (h), (i), or (j); wherein the nucleic acid molecule is operably linked to an expression control sequence.

9. (withdrawn)

10. (currently amended) A polypeptide encoded by a nucleic acid molecule selected from:

a) a nucleotide sequence as set forth in Figure 2A (SEQ ID NO: 6) or Figure 3A (SEQ ID NO: 11);

b) a nucleotide sequence encoding the polypeptide as set forth in Figure 2A (SEQ ID NO. 7) from residues 1-322 or from residues 47-322;

c) a nucleotide sequence encoding a polypeptide that is at least about 95 ~~[[70]]~~ percent identical to the polypeptide as set forth in Figure 2A (SEQ ID NO: 6) or Figure 3A (SEQ ID NO: 11), wherein the isolated polypeptide has at least one activity characteristic of B7RP1 selected from a T-cell proliferation activity, a T-cell activation activity, and a binding activity to CRP1;

~~d) a nucleotide sequence complementary to any of (a), (b), or (c);~~

(d) [(e)] a nucleotide sequence of (b) or (c) encoding a polypeptide fragment of at least about 50 amino acid residues, wherein the polypeptide fragment has at least one activity characteristic of B7RP1 selected from a T-cell proliferation activity, a T-cell activation activity, and a binding activity to CRP1;

e) [[f]] a nucleotide sequence of comprising a fragment of at least about 75 nucleotides of the sequence as set forth in Figure 2A (SEQ ID NO: 6) or Figure 3A (SEQ ID [[S]] NO: 11), wherein the polypeptide fragment has at least one activity characteristic of B7RP1 selected from a T-cell proliferation activity, a T-cell activation activity, and a binding activity to CRP1; and

f) [[g]] a nucleotide sequence that hybridizes over its entire length to any of (a)-(e) under high stringency conditions comprising a hybridization medium of 50% (volume/volume) formamide with 0.1% bovine serum albumin/0.1% Ficoll/0.1% polyvinylpyrrolidone/50 mM sodium phosphate buffer at pH 6.5 with 5 x SSC at 42°C and washes at 42°C in 0.2 x SSC and 0.1% SDS, where the polypeptide encoded by the complement of the sequence has at least one activity selected from a T-cell proliferation activity, a T-cell activation activity, and a binding activity to B7RP1 to any of (a)-(f); and

h) a nucleotide sequence complementary to any of (a)-(f).

11. (withdrawn)

12. (currently amended) An isolated polypeptide comprising an amino acid sequence selected from ~~the group consisting of:~~

a) an amino acid sequence as set forth in Figure 2A (SEQ ID NO: 7) or Figure 3A (SEQ ID NO: 12);

b) a mature amino acid sequence as set forth in Figure 2A (SEQ ID NO: 7) comprising a mature amino terminus at residue 47, or Figure 3A (SEQ ID NO: 12) comprising a mature amino terminus at any of residues 19, 20, 21, 22, 24, or 28, or Figure 12A (SEQ ID NO: 17) comprising a mature amino terminus at any of residues 19, 20, 21, 22, 24, or 28; and

c) a fragment of an amino acid sequence set forth in Figure 2A (SEQ ID NO: 7) or Figure 3A (SEQ ID NO: 12) comprising at least about 50 amino acid residues, wherein the fragment has at least one activity ~~characteristic of B7RP1~~; selected from a T-cell proliferation activity, a T-cell activation activity, and a binding activity to CRP1.

13-18 (withdrawn)

19. (previously presented) A composition comprising a polypeptide and a pharmaceutically acceptable carrier, adjuvant, solubilizer, stabilizer or anti-oxidant, wherein the polypeptide is the isolated polypeptide of claims 8, 10, or 12.

20. (previously presented) A polypeptide comprising a derivative of a polypeptide of claims 8, 10, or 12.

21. (original) The polypeptide of Claim 20 which is covalently modified with a water-soluble polymer.

22. (currently amended) A fusion polypeptide comprising a polypeptide of Claims 8, 10, [[,]] or 12 fused to a heterologous amino acid sequence.

23. (original) The fusion polypeptide of claim 22, wherein the heterologous amino acid sequence is an IgG constant domain or fragment thereof.

24-42 (withdrawn)

43. (previously presented) The isolated polypeptide of claim 12 comprising an amino acid sequence as set forth in Figure 2A (SEQ ID NO: 7) or Figure 3A (SEQ ID NO: 12).

44. (previously presented) The isolated polypeptide of claim 12 consisting of an amino acid sequence as set forth in Figure 2A (SEQ ID NO: 7) or Figure 3A (SEQ ID NO: 12).

45. (currently amended) The isolated polypeptide of claim 12 comprising a fragment of an amino acid sequence as set forth in Figure 2A (SEQ ID NO: 7) or Figure 3A (SEQ ID NO: 12) comprising at least about 50 amino acid residues, wherein the fragment has at least one activity ~~characteristic of B7RP4~~ selected from a T-cell proliferation activity, a T-cell activation activity, and a binding activity to CRP1.

46. (currently amended) An isolated polypeptide comprising an amino acid sequence that is at least about 95 ~~[[70]]~~ percent identical to an amino acid sequence as set forth in Figure 2A (SEQ ID NO: 6) or Figure 3A (SEQ ID NO: 12), wherein the isolated polypeptide has at least one activity ~~characteristic of B7RP4~~ selected from a T-cell proliferation activity, a T-cell activation activity, and a binding activity to CRP1.

47. (currently amended) An isolated polypeptide comprising a fragment of at least about 50 amino acid residues; wherein the fragment comprises an amino acid sequence that is at least about 95 ~~[[70]]~~ percent identical to an amino acid sequence as set forth in Figure 2A (SEQ ID NO: 6) or Figure 3A (SEQ ID: NO 12); and wherein the fragment has at least one activity ~~characteristic of B7RP4~~ selected from a T-cell proliferation activity, a T-cell activation activity, and a binding activity to CRP1.

48. (currently amended) An isolated polypeptide comprising an amino acid sequence as set forth in Figure 12A (SEQ ID NO. 17) with a mature amino terminus at any of residues 19, 20, 21, 22, 24, or 28, wherein the isolated polypeptide has at least one activity ~~characteristic of B7RP4~~ selected from a T-cell proliferation activity, a T-cell activation activity, and a binding activity to CRP1.

49. (currently amended) An isolated polypeptide comprising an amino acid sequence as set forth in Figure 12A (SEQ ID NO. 17) comprising a carboxy terminus at ~~about~~ residue 302, wherein the polypeptide has at least one activity ~~characteristic of B7RP4~~ selected from a T-cell proliferation activity, a T-cell activation activity, and a binding activity to CRP1.

50. (previously presented) An isolated polypeptide comprising an amino acid sequence as set forth in Figure 12A (SEQ ID NO: 17).

51. (previously presented) An isolated polypeptide consisting of an amino acid sequence as set forth in Figure 12A (SEQ ID NO: 17).

52. (previously presented) The isolated polypeptide of claim 10 encoded by a nucleic acid molecule comprising a sequence as set forth in Figure 2A (SEQ ID NO: 6) or Figure 3A (SEQ ID NO: 11).

53. (currently amended) The isolated polypeptide of claim 10 encoded by a nucleic acid molecule which is capable of hybridizing over its entire length to a nucleic acid molecule that is complementary to a nucleic acid molecule as set forth in Figure 2A (SEQ ID NO: 6) or Figure 3A (SEQ ID NO: 11) under high stringency conditions comprising a hybridization medium of 50% (volume/volume) formamide with 0.1% bovine serum albumin/0.1% Ficoll/0.1% polyvinylpyrrolidone/50 mM sodium phosphate buffer at pH 6.5 with 5 x SSC at 42°C and washes at 42°C in 0.2 x SSC and 0.1% SDS, where the polypeptide has at least one activity selected from a T-cell proliferation activity, a T-cell activation activity, and a binding activity to B7RP1.

54. (currently amended) The isolated polypeptide of claim 10, wherein the isolated polypeptide is encoded by a nucleic acid molecule comprising a sequence that is at least about 95% identical to a nucleic acid as set forth in Figure 2A (SEQ ID NO: 6) or Figure 3A (SEQ ID NO: 11) and wherein the isolated polypeptide has at least one activity ~~characteristic of B7RP1~~ selected from a T-cell proliferation activity, a T-cell activation activity, and a binding activity to CRP1.

55. (previously presented) An isolated polypeptide encoded by a nucleic acid molecule consisting of a nucleotide sequence as set forth in Figure 12A (SEQ ID NO: 16).

FINNEGAN
HENDERSON
FARABOW
GARRETT &
DUNNER LLP

1300 I Street, NW
Washington, DC 20005
202.408.4000
Fax 202.408.4400
www.finnegan.com